{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059130","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.616036+00:00","generated_at":"2026-06-02T05:31:28.517144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized","bullets":["Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.","Cash $56.5M as of March 31, 2024; expected to fund operations into Q3 2025.","Pipeline reprioritization: CT-0525 becomes lead; CT-0508 enrollment ceased; CT-1119 paused; workforce reduced ~37%.","Initial CT-0525 Phase 1 data expected by year-end 2024; preclinical fibrosis data presented at ASGCT.","Appointed Eugene Kennedy as CMO; John Hohneker to Board; Chidozie Ugwumba resigned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059130","json":"https://secwatch.observer/filing/0001104659-24-059130.json","markdown":"https://secwatch.observer/filing/0001104659-24-059130.md","text":"https://secwatch.observer/filing/0001104659-24-059130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/0001104659-24-059130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/tm2413903d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:31:28.517144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54127c8f1c37d25178389f416beb645fd4a2f78f","claim":"Carisma Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/0001104659-24-059130-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}